Welcome to our dedicated page for Journey Medical Corporation news (Ticker: DERM), a resource for investors and traders seeking the latest updates and insights on Journey Medical Corporation stock.
Journey Medical Corporation (symbol: DERM) is a commercial stage pharmaceutical company dedicated to the development and commercialization of products designed to treat dermatological conditions. With a diverse portfolio that includes eight branded and three authorized generic prescription drugs marketed in the United States, Journey Medical is committed to improving the quality of life for patients with skin conditions.
Among the well-known products in their lineup are Qbrexza, a topical treatment for excessive underarm sweating, Accutane, a potent medication for severe acne, Amzeeq, a foam treatment for acne vulgaris, and Exelderm, an antifungal solution. These products highlight the company's dedication to addressing various dermatological needs.
Recently, Journey Medical secured additional capital to support general corporate purposes, including funding for the potential launch of DFD-29. This demonstrates their strategic effort to expand their product offerings and enhance their market presence.
The company is proactive in maintaining transparent communication with its stakeholders. They have scheduled a conference call on March 21, 2024, to discuss financial results and provide a corporate update. Furthermore, another conference call is set for May 13, 2024.
Looking ahead, an important milestone for Journey Medical is the Prescription Drug User Fee Act (PDUFA) goal date on November 4, 2024. This date is crucial for the approval process of their new drug applications, reflecting the company's ongoing efforts in drug development and commercialization.
For more information, investors and interested parties can contact Jaclyn Jaffe at (781) 652-4500 or via email at ir@jmcderm.com. Media inquiries can be directed to Tony Plohoros at (908) 591-2839 or tplohoros@6degreespr.com.
Journey Medical (Nasdaq: DERM) reported a 7% year-over-year increase in total revenues for Q1 2024, reaching $13 million. This growth was driven by significant increases in the sales of Qbrexza and Accutane, despite declines in other products like Amzeeq and Zilxi. The company reported a net loss of $10.4 million, slightly higher than the $10.1 million loss in Q1 2023. Research and development expenses surged due to a $4 million FDA filing fee and a $3 million milestone payment. Journey Medical's New Drug Application for DFD-29 to treat rosacea has been accepted by the FDA, with a PDUFA goal date of November 4, 2024, potentially making it a leading systemic therapy for rosacea.
Journey Medical , a pharmaceutical company specializing in dermatological products, will announce its first quarter 2024 financial results on May 13, 2024. The company will host a conference call to discuss the results and provide a corporate update at 4:30 p.m. ET on the same day.
Journey Medical has appointed Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Benesch brings over 25 years of experience in financial leadership and reporting, with a focus on the pharmaceutical industry. The company's Co-Founder, President, and CEO praised Benesch's expertise and contributions to the finance and accounting team, emphasizing his role in upcoming milestones like the potential approval of DFD-29 for rosacea treatment. Benesch's extensive background includes positions at Teligent Pharma Inc., Torrent Pharmaceuticals, Savient Pharmaceuticals, Adare Pharmaceuticals, and Edenbridge Pharmaceuticals, along with experience at Baker Tilly Virchow Krause, LLP, and Ernst and Young. With a BA in accounting and CPA certification from Wilkes University, Benesch aims to drive sustainable value for Journey Medical and its shareholders while supporting patients with dermatological products.
FAQ
What is the current stock price of Journey Medical Corporation (DERM)?
What is the market cap of Journey Medical Corporation (DERM)?
What does Journey Medical Corporation do?
What are some of Journey Medical's key products?
What recent achievements has Journey Medical Corporation made?
When is the next conference call for Journey Medical?
What is the PDUFA goal date for Journey Medical?
How can I contact Journey Medical for investor relations?
Who handles media relations for Journey Medical?
What is DFD-29?
Where are Journey Medical's products marketed?
What is the focus of Journey Medical Corporation?
